Newsroom

Press Release

NeoGenomics Announces Proposed Public Offering of Common Stock

NeoGenomics Announces Pricing on Public Offering of Common Stock

NeoGenomics Announces Proposed Public Offering of Common Stock

NeoGenomics Reports Record Revenue of $67.7 Million with 14% Increase in Clinical Volume Growth and 95% Increase in Pharma Services Backlog

NeoGenomics Schedules its Second Quarter Earnings Release for July 24, 2018

NeoGenomics Redeems 100% of Series A Redeemable Preferred Stock

PPD and NeoGenomics Forming Global Strategic Alliance for Pathology and Molecular Testing Solutions

NeoGenomics to Participate In Two Upcoming Investor Conferences

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients